Celltrion Data Supports Subcutaneous Remisma For IBD
Also Backs Biosimilar For Crohn’s Disease And Ulcerative Colitis
Executive Summary
Celltrion has published Phase I data supporting the use of its subcutaneous formulation of biosimilar infliximab to treat inflammatory bowel disease. The results follow a positive CHMP opinion for using subcutaneous Remsima to treat rheumatoid arthritis.